Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Gemcitabine Versus Cisplatin and Gemcitabine in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer in Poor Physical Condition (Performance Status 2)
Brief Summary: The primary objective of this study is to evaluate the impact on overall survival (OS) of the addition of cisplatin to gemcitabine vs gemcitabine alone in patients with advanced NSCLC in poor clinical condition (PS 2), not previously treated.


Options:
A: Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: gemcitabine, Drug: cisplatin | Arm Label: Arm A; Type: ACTIVE_COMPARATOR; Interventions: Drug: gemcitabine | Intervention Type: DRUG; Name: gemcitabine; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): Arm B
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Docetaxel, Drug: Gemcitabine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Gemcitabine | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): 2
C: Arm Label: IMC-1121B + Pemetrexed + Carboplatin (AUC 6) or Cisplatin; Type: EXPERIMENTAL; Interventions: Biological: IMC-1121B (ramucirumab), Drug: Pemetrexed, Drug: Carboplatin (AUC 6), Drug: Cisplatin | Arm Label: Pemetrexed + Carboplatin (AUC 6) or Cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pemetrexed, Drug: Carboplatin (AUC 6), Drug: Cisplatin | Arm Label: IMC-1121B + Gemcitabine + Carboplatin (AUC 5) or Cisplatin; Type: EXPERIMENTAL; Interventions: Biological: IMC-1121B (ramucirumab), Drug: Cisplatin, Drug: Gemcitabine, Drug: Carboplatin (AUC 5) | Arm Label: Gemcitabine + Carboplatin (AUC 5) or Cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cisplatin, Drug: Gemcitabine, Drug: Carboplatin (AUC 5) | Intervention Type: BIOLOGICAL; Name: IMC-1121B (ramucirumab); Assigned to Arm(s): IMC-1121B + Gemcitabine + Carboplatin (AUC 5) or Cisplatin, IMC-1121B + Pemetrexed + Carboplatin (AUC 6) or Cisplatin | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): IMC-1121B + Pemetrexed + Carboplatin (AUC 6) or Cisplatin, Pemetrexed + Carboplatin (AUC 6) or Cisplatin | Intervention Type: DRUG; Name: Carboplatin (AUC 6); Assigned to Arm(s): IMC-1121B + Pemetrexed + Carboplatin (AUC 6) or Cisplatin, Pemetrexed + Carboplatin (AUC 6) or Cisplatin | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Gemcitabine + Carboplatin (AUC 5) or Cisplatin, IMC-1121B + Gemcitabine + Carboplatin (AUC 5) or Cisplatin, IMC-1121B + Pemetrexed + Carboplatin (AUC 6) or Cisplatin, Pemetrexed + Carboplatin (AUC 6) or Cisplatin | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Gemcitabine + Carboplatin (AUC 5) or Cisplatin, IMC-1121B + Gemcitabine + Carboplatin (AUC 5) or Cisplatin | Intervention Type: DRUG; Name: Carboplatin (AUC 5); Assigned to Arm(s): Gemcitabine + Carboplatin (AUC 5) or Cisplatin, IMC-1121B + Gemcitabine + Carboplatin (AUC 5) or Cisplatin
D: Arm Label: Arm A: Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Arm B: Docetaxel; Type: EXPERIMENTAL; Interventions: Drug: Docetaxel | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Arm B: Docetaxel

Answer: A